Michitsugu Kamezaki
Overview
Explore the profile of Michitsugu Kamezaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tomita-Yagi A, Ozeki-Okuno N, Watanabe-Uehara N, Komaki K, Umehara M, Sawada-Yamauchi H, et al.
iScience
. 2024 Feb;
27(2):109020.
PMID: 38357667
The immense public health burden of diabetic kidney disease (DKD) has led to an increase in research on the pathophysiology of advanced DKD. The present study focused on the significance...
2.
Yamamoto S, Kamezaki M, Ooka J, Mazaki T, Shimoda Y, Nishihara T, et al.
World J Clin Cases
. 2023 Dec;
11(35):8364-8371.
PMID: 38130610
Background: Although superior vena cava (SVC) syndrome has also been reported as a late complication of pacemaker (PM) implantation, acute onset of SVC syndrome caused by disdialysis syndrome in patients...
3.
Nakai K, Umehara M, Minamida A, Yamauchi-Sawada H, Sunahara Y, Matoba Y, et al.
Sci Rep
. 2023 May;
13(1):8705.
PMID: 37248327
Streptozotocin (STZ), an anti-cancer drug that is primarily used to treat neuroendocrine tumors (NETs) in clinical settings, is incorporated into pancreatic β-cells or proximal tubular epithelial cells through the glucose...
4.
Uehara-Watanabe N, Okuno-Ozeki N, Nakamura I, Nakata T, Nakai K, Yagi-Tomita A, et al.
Heliyon
. 2022 Sep;
8(9):e10615.
PMID: 36148274
Based on recent clinical trials using sodium-glucose co-transporter 2 inhibitor (SGLT2i) demonstrating the significant improvement of outcomes of diabetic kidney disease (DKD), the paradigm shift from "glomerulocentric" to "tubule centric"...
5.
Uehara-Watanabe N, Okuno-Ozeki N, Minamida A, Nakamura I, Nakata T, Nakai K, et al.
Sci Rep
. 2022 Jan;
12(1):778.
PMID: 35039597
Kidney hypertrophy is a common clinical feature in patients with diabetes and is associated with poor renal outcomes. Initial cell proliferation followed by cellular hypertrophy are considered the responsible mechanisms...
6.
Kamezaki M, Kusaba T, Komaki K, Fushimura Y, Watanabe N, Ikeda K, et al.
Sci Rep
. 2018 Mar;
8(1):4029.
PMID: 29507299
Clinical and experimental studies have shown that sodium glucose co-transporter 2 inhibitors (SGLT2i) contribute to the prevention of diabetic kidney disease progression. In order to clarify its pharmacological effects on...
7.
Tamoto Y, Ishida R, Shiogama K, Kado H, Kamezaki M, Chinen Y, et al.
Intern Med
. 2017 Aug;
56(15):2007-2012.
PMID: 28768972
A 62-year-old man exhibiting nasal obstruction and glomerulonephritis with proteinase 3-antineutrophil cytoplasmic antibodies (PR3-ANCAs) was diagnosed with extranodal NK/T-cell lymphoma, nasal type (ENKL) with infiltration of neutrophils with apoptosis. Chemoradiotherapy...
8.
Kamezaki M, Kusaba T, Adachi T, Yamashita N, Nakata M, Ota N, et al.
Intern Med
. 2017 Jun;
56(11):1393-1397.
PMID: 28566604
Hypoparathyroidism, sensorineural deafness, and renal dysplasia (HDR) syndrome is a rare autosomal dominant disease caused by GATA3 mutations. Although several cases with variable renal features have been reported, the presence...
9.
Kamezaki M, Kakimoto T, Takeuchi T, Akuta K, Kasahara H, Yamamoto K, et al.
Leuk Lymphoma
. 2012 Mar;
53(10):2083-4.
PMID: 22397315
No abstract available.